Award

SMA Newborn Screening Kits

NHS GREATER GLASGOW AND CLYDE

This public procurement record has 2 releases in its history.

Summary of the contracting process

The contracting process for the procurement of SMA Newborn Screening Kits has been completed by NHS Greater Glasgow and Clyde. This procurement falls under the health industry category, specifically focusing on genetic screening for Spinal Muscular Atrophy (SMA) in newborns. The contract, valued at £237,847, was awarded to Labsystems Diagnostics OY, a supplier recognised for its specialised screening kits. Key details include the procurement method, which involved a limited procedure without prior publication due to the absence of competition for technical reasons as established by Regulation 33. The contract was signed on 5th March 2026, with the screening required to comply with the Scottish screening protocol, thereby providing significant health benefits to the local population in the Glasgow region (UKM82).

This tender represents an opportunity for businesses specialising in medical diagnostics and genetic screening to explore potential collaborations with NHS Greater Glasgow and Clyde. Companies that can provide innovative screening technologies conforming to regional protocols, specifically those involving gene measurement like SMN1 and SMN2, are well-positioned to compete for related contracts. Such businesses, particularly SMEs and those operating within the EU, could benefit from forging relationships with public health bodies and contribute to advancements in genetic diagnostics, thereby enhancing their portfolio and market positioning in the healthcare sector.

Find more tenders on our Open Data Platform.
How relevant is this notice?

Notice Title

SMA Newborn Screening Kits

Notice Description

The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).

Lot Information

Lot 1

The Scottish Newborn Screening Laboratory has been commissioned to participate in the in service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement to screen died blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA). Scotland has begun a 2 year evaluation of SMA screening on behalf of the National Screening Committee to gather data to allow a decision to be made about if SMA screening should be included in the UK Newborn Screening Panel. SMA is cause by a deletion of the SMN1 gene, but the severity of the disease depends on another gene called SMN2. SMN2 is present in all babies in various copy numbers, and the lower the copy number the more severe the disease.

Procurement Information

In order to award this contract compliantly, NHSGGC will follow Regulation 33. (b)where the works, supplies or services can be supplied only by a particular economic operator for any of the following reasons (ii)competition is absent for technical reasons. There are several commercial kits available for screening for SMA. This means if an alternative kit is used, SMA can be detected but not the variability or severity of this disease. The screening pathway established in Scotland by clinicians includes measurement of SMN1 and also measurement of SMN2 copy numbers. Therefore, to allow the laboratory to fulfil the Scottish screening pathway, SMN2 copy numbers must be measured in addition to the SMN1 deletion. The only identified solution is the proposed awarded kit. This adheres to the recommended screening pathway in Scotland. The benefit to the patient is that the full severity of the disease will be known at the initial appointment with the clinical team. In traditional pathways the patient will have to wait for diagnostic testing. Patients with the most severe forms of SMA have very severe symptoms caused by muscle wastage. This results in reduced movement, often resulting in an inability to sit or walk, and the need for breathing and feeding tubes. If the baby is able to start treatment before these symptoms present, they will likely never develop these symptoms. By knowing the severity of the disease as early as possible, gives the best chance for treatment to be given pre-symptomatically, thus reducing the morbidity and morality associated with this disease. In addition to this, there is significant published evidence to show that having the disease severity known at the initial appointment reduces anxiety for the family. No other commercial kits for SMA screening include the SMN2 copy number. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol.

Publication & Lifecycle

Open Contracting ID
ocds-r6ebe6-0000826401
Publication Source
Public Contracts Scotland
Latest Notice
https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=APR553217
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
OJEU - F3 - Contract Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Limited
Procurement Method Details
Award procedure without prior publication of a call for competition
Tender Suitability
Not specified
Awardee Scale
SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products


CPV Codes

33696500 - Laboratory reagents

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£237,847 £100K-£500K

Notice Dates

Publication Date
2 Apr 20262 days ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
5 Mar 20261 months ago
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Not Specified
Contracts Status
Active

Contracting Authority (Buyer)

Main Buyer
NHS GREATER GLASGOW AND CLYDE
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
GLASGOW
Postcode
G4 0SF
Post Town
Glasgow
Country
Scotland

Major Region (ITL 1)
TLM Scotland
Basic Region (ITL 2)
TLM3 West Central Scotland
Small Region (ITL 3)
TLM32 Glasgow City
Delivery Location
TLM82 Glasgow City

Local Authority
Glasgow City
Electoral Ward
Dennistoun
Westminster Constituency
Glasgow North East

Supplier Information

Number of Suppliers
1
Supplier Name

LABSYSTEMS DIAGNOSTICS

Further Information

Notice Documents

  • https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552048
    SMA Newborn Screening Kits - The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).
  • https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=APR553217
    SMA Newborn Screening Kits - The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-r6ebe6-0000826401-2026-04-02T00:00:00Z",
    "date": "2026-04-02T00:00:00Z",
    "ocid": "ocds-r6ebe6-0000826401",
    "initiationType": "tender",
    "parties": [
        {
            "id": "org-43",
            "name": "NHS Greater Glasgow and Clyde",
            "identifier": {
                "legalName": "NHS Greater Glasgow and Clyde"
            },
            "address": {
                "streetAddress": "Procurement Department, Glasgow Royal Infirmary, 84 Castle Street",
                "locality": "Glasgow",
                "region": "UKM82",
                "postalCode": "G4 0SF"
            },
            "contactPoint": {
                "email": "william.cullen@nhs.scot",
                "telephone": "+44 1412015388",
                "url": "http://"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "classifications": [
                    {
                        "id": "Body governed by public law",
                        "scheme": "TED_CA_TYPE"
                    },
                    {
                        "id": "07",
                        "description": "Health",
                        "scheme": "COFOG"
                    }
                ],
                "url": "http://www.nhsggc.scot/about-us/procurement/"
            }
        },
        {
            "id": "org-44",
            "name": "Labsystems Diagnostics OY",
            "identifier": {
                "legalName": "Labsystems Diagnostics OY"
            },
            "address": {
                "streetAddress": "Tiilitie 3, Finlandia",
                "locality": "Vantaa",
                "region": "FI1B",
                "postalCode": "01720"
            },
            "contactPoint": {
                "email": "sales@ladsystemsdx.com",
                "telephone": "+44 358201557530"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "sme",
                "url": "http://"
            }
        },
        {
            "id": "org-45",
            "name": "Glasgow Sheriff Court",
            "identifier": {
                "legalName": "Glasgow Sheriff Court"
            },
            "address": {
                "streetAddress": "PO Box 23, 1 Carlton Place",
                "locality": "Glasgow",
                "postalCode": "G5 9DA"
            },
            "contactPoint": {
                "url": "http://"
            },
            "roles": [
                "reviewBody"
            ]
        },
        {
            "id": "org-19",
            "name": "NHS Greater Glasgow and Clyde",
            "identifier": {
                "legalName": "NHS Greater Glasgow and Clyde"
            },
            "address": {
                "streetAddress": "Procurement Department, Glasgow Royal Infirmary, 84 Castle Street",
                "locality": "Glasgow",
                "region": "UKM82",
                "postalCode": "G4 0SF"
            },
            "contactPoint": {
                "email": "william.cullen@nhs.scot",
                "telephone": "+44 1412015388",
                "url": "http://"
            },
            "roles": [
                "buyer",
                "centralPurchasingBody"
            ],
            "details": {
                "classifications": [
                    {
                        "id": "Body governed by public law",
                        "scheme": "TED_CA_TYPE"
                    },
                    {
                        "id": "07",
                        "description": "Health",
                        "scheme": "COFOG"
                    }
                ],
                "url": "http://www.nhsggc.scot/about-us/procurement/"
            }
        },
        {
            "id": "org-20",
            "name": "Labsystems Diagnostics OY",
            "identifier": {
                "legalName": "Labsystems Diagnostics OY"
            },
            "address": {
                "streetAddress": "Tiilitie 3, Finlandia",
                "locality": "Vantaa",
                "region": "FI1B",
                "postalCode": "01720"
            },
            "contactPoint": {
                "email": "sales@ladsystemsdx.com",
                "telephone": "+44 358201557530"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "sme",
                "url": "http://"
            }
        },
        {
            "id": "org-21",
            "name": "Glasgow Sheriff Court",
            "identifier": {
                "legalName": "Glasgow Sheriff Court"
            },
            "address": {
                "streetAddress": "PO Box 23, 1 Carlton Place",
                "locality": "Glasgow",
                "postalCode": "G5 9DA"
            },
            "contactPoint": {
                "url": "http://"
            },
            "roles": [
                "reviewBody"
            ]
        }
    ],
    "buyer": {
        "name": "NHS Greater Glasgow and Clyde",
        "id": "org-19"
    },
    "tender": {
        "id": "ocds-r6ebe6-0000826401",
        "title": "SMA Newborn Screening Kits",
        "description": "The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).",
        "status": "complete",
        "items": [
            {
                "id": "1",
                "additionalClassifications": [
                    {
                        "id": "33696500",
                        "scheme": "CPV"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UKM82"
                    },
                    {
                        "region": "UKM82"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "procurementMethod": "limited",
        "procurementMethodDetails": "Award procedure without prior publication of a call for competition",
        "procurementMethodRationale": "In order to award this contract compliantly, NHSGGC will follow Regulation 33. (b)where the works, supplies or services can be supplied only by a particular economic operator for any of the following reasons (ii)competition is absent for technical reasons. There are several commercial kits available for screening for SMA. This means if an alternative kit is used, SMA can be detected but not the variability or severity of this disease. The screening pathway established in Scotland by clinicians includes measurement of SMN1 and also measurement of SMN2 copy numbers. Therefore, to allow the laboratory to fulfil the Scottish screening pathway, SMN2 copy numbers must be measured in addition to the SMN1 deletion. The only identified solution is the proposed awarded kit. This adheres to the recommended screening pathway in Scotland. The benefit to the patient is that the full severity of the disease will be known at the initial appointment with the clinical team. In traditional pathways the patient will have to wait for diagnostic testing. Patients with the most severe forms of SMA have very severe symptoms caused by muscle wastage. This results in reduced movement, often resulting in an inability to sit or walk, and the need for breathing and feeding tubes. If the baby is able to start treatment before these symptoms present, they will likely never develop these symptoms. By knowing the severity of the disease as early as possible, gives the best chance for treatment to be given pre-symptomatically, thus reducing the morbidity and morality associated with this disease. In addition to this, there is significant published evidence to show that having the disease severity known at the initial appointment reduces anxiety for the family. No other commercial kits for SMA screening include the SMN2 copy number. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol.",
        "mainProcurementCategory": "goods",
        "documents": [
            {
                "id": "MAR552048",
                "documentType": "awardNotice",
                "title": "SMA Newborn Screening Kits",
                "description": "The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).",
                "url": "https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=MAR552048",
                "format": "text/html"
            },
            {
                "id": "APR553217",
                "documentType": "awardNotice",
                "title": "SMA Newborn Screening Kits",
                "description": "The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA).",
                "url": "https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=APR553217",
                "format": "text/html"
            }
        ],
        "lots": [
            {
                "id": "1",
                "description": "The Scottish Newborn Screening Laboratory has been commissioned to participate in the in service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee. NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement to screen died blood spot samples from newborn babies for Spinal Muscular Atrophy (SMA). Scotland has begun a 2 year evaluation of SMA screening on behalf of the National Screening Committee to gather data to allow a decision to be made about if SMA screening should be included in the UK Newborn Screening Panel. SMA is cause by a deletion of the SMN1 gene, but the severity of the disease depends on another gene called SMN2. SMN2 is present in all babies in various copy numbers, and the lower the copy number the more severe the disease.",
                "status": "complete",
                "hasOptions": false,
                "awardCriteria": {
                    "criteria": [
                        {
                            "type": "quality",
                            "name": "Quality",
                            "description": "99"
                        },
                        {
                            "type": "price",
                            "description": "1"
                        }
                    ]
                }
            }
        ],
        "coveredBy": [
            "GPA"
        ],
        "procurementMethodRationaleClassifications": [
            {
                "id": "D_OUTSIDE_SCOPE",
                "description": "The procurement falls outside the scope of application of the directive"
            }
        ],
        "classification": {
            "id": "33696500",
            "scheme": "CPV"
        },
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        }
    },
    "awards": [
        {
            "id": "ocds-r6ebe6-0000826401-1",
            "suppliers": [
                {
                    "id": "org-44",
                    "name": "Labsystems Diagnostics OY"
                },
                {
                    "id": "org-20",
                    "name": "Labsystems Diagnostics OY"
                }
            ],
            "relatedLots": [
                "1"
            ]
        }
    ],
    "contracts": [
        {
            "id": "ocds-r6ebe6-0000826401-1",
            "awardID": "ocds-r6ebe6-0000826401-1",
            "status": "active",
            "value": {
                "amount": 237847,
                "currency": "GBP"
            },
            "dateSigned": "2026-03-05T00:00:00Z"
        }
    ],
    "language": "EN",
    "description": "No other commercial kits for SMA screening include the SMN2 copy number. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. (SC Ref:828095)",
    "links": [
        {
            "rel": "canonical",
            "href": "https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000826401"
        },
        {
            "rel": "canonical",
            "href": "https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000826401"
        }
    ],
    "noticetype": "OJEU - F3 - Contract Award Notice",
    "relatedProcesses": [
        {
            "id": "1",
            "relationship": [
                "planning"
            ],
            "scheme": "EU-OJ",
            "identifier": "2026/S 000-025039"
        }
    ],
    "bids": {
        "statistics": [
            {
                "id": "36",
                "measure": "bids",
                "value": 1,
                "relatedLot": "1"
            },
            {
                "id": "37",
                "measure": "smeBids",
                "value": 1,
                "relatedLot": "1"
            },
            {
                "id": "38",
                "measure": "foreignBidsFromEU",
                "value": 1,
                "relatedLot": "1"
            },
            {
                "id": "39",
                "measure": "foreignBidsFromNonEU",
                "value": 0,
                "relatedLot": "1"
            },
            {
                "id": "40",
                "measure": "electronicBids",
                "value": 1,
                "relatedLot": "1"
            }
        ]
    }
}